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Ketamine, a Brighter Future for Those 
in Darkness
Matthew Gayhart, Faculty Mentor: Bonnie Boaz
Abstract
Millions of people around the world suffer from Major Depressive 
Disorder, and many of these people are given drugs to help treat this 
potentially devastating disease. For many, the first treatment is 
successful, and if not, certainly the second treatment gives them the 
relief they so desperately need. Others, however, are not so lucky, 
people with treatment resistant depression undergo numerous 
treatments, some of which are more aggressive than others, but still 
nothing helps alleviate their depression. Recently an older anesthetic, the 
drug Ketamine, has been making some news as a new depression 
treatment. This paper will compare Ketamine to the traditional 
approaches for treating depression, as well as discuss the next steps in 
making this drug more widely available. By reviewing scholarship on the 
subject of antidepressants, as well as available research on Ketamine, 
and by interviewing a patient who recently underwent a Ketamine 
treatment, this research highlights the positive results of Ketamine while 
acknowledging the setbacks that still currently exist, and advocates for 
the use of Ketamine as a treatment for depression. 
Ketamine Facts
Ketamine was developed in 1962 as an anesthetic, it was used in 
Vietnam on the battlefield, for it was an anesthetic that did not affect 
the respiratory system, so only one doctor was needed. Since then, 
Ketamine has made its way onto the Drug Enforcement 
Administration’s radar as a schedule III non narcotic substance 
(Sewell, 2007). 
The Ketamine treatment involves 6 infusions of a low dosage of 
Ketamine over the course of two weeks.
The effects of traditional antidepressants take several weeks to 
become appreciable. Ketamine’s effects are seen usually within 24 
hours of the first treatment. 
Results/Discussion
Many clinical trials have been performed  using Ketamine, 
however, none of them have included a placebo group. The trials 
primarily focus on the relation between the Ketamine treatments 
and the changes in the patient’s depression and or suicidality levels. 
Rot, et.al (2010) did one such study, in which they treated ten 
patients with six infusions of Ketamine over the course of two 
weeks. They recorded the patients’ depression levels prior to and 
after each infusion. They found that the average reduction in 
depression levels was 85% (Rot).  They found reductions of that 
level after the two week treatment was completed, most typical 
antidepressants take that long or longer to show any effect at all, 
and even then it is not usually as pronounced as with Ketamine. Dr. 
Levine (2013), is one of the handful of doctors that currently offers 
the Ketamine treatment, and he has personally completed the 
treatment on over 100 patients. He reports that he has not had a 
single case with any negative side effects, nor any lasting negative 
reactions. His results also fall in line with previous tests, with a high 
percentage of patients having a significant decrease in depression 
levels (Levine). Ketamine has produced positive results for 
individuals who may never have experienced a successful 
depression treatment.
Conclusion
Ketamine has the potential to save thousands of lives every single year, but 
there are still a few problems standing in the way of it truly being a viable 
option to treat depression. First, there are not enough doctors or hospitals 
offering the treatment, as it is highly specialized and is not an approved 
treatment. Second, the cost of Ketamine can be high; this comes in part from 
the lack of insurance support. Insurance would be more likely to cover the cost 
of the treatment if it were an FDA approved treatment for depression. 
However, regardless of these shortfalls hindering the widespread use of 
Ketamine, the drug is out there and, while there may be a waiting list and an 
extremely large price tag, relief can be reached by many. With public support, 
Ketamine can be seen as the life saving drug that it has the potential to be, but 
the first step towards change is knowledge. More trials and more research must 
be conducted on the safety and efficacy of Ketamine, but that should not stop 
it from saving people, people who have no where else to turn.
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Steven P. Levine, M.D.
One of the few doctors in the country to 
offer Ketamine infusions. He is based in 
Princeton, NJ and is willing to help anyone 
who is suffering. 
